300406 九强生物
已收盘 09-04 15:00:00
资讯
新帖
简况
九强生物最新公告：取得叶酸测定试剂盒医疗器械注册证
证券之星 · 09-02 17:16
九强生物最新公告：取得叶酸测定试剂盒医疗器械注册证
股市必读：九强生物新发布《第五届董事会第二十七次会议决议公告》
证券之星 · 09-02
股市必读：九强生物新发布《第五届董事会第二十七次会议决议公告》
九强生物（300406）披露召开2026年第二次临时股东会的通知，9月1日股价上涨1.11%
证券之星 · 09-01
九强生物（300406）披露召开2026年第二次临时股东会的通知，9月1日股价上涨1.11%
股市必读：九强生物（300406）8月25日董秘有最新回复
证券之星 · 08-26
股市必读：九强生物（300406）8月25日董秘有最新回复
九强生物（300406）2026年中报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 08-23
九强生物（300406）2026年中报简析：营收净利润同比双双增长，盈利能力上升
九强生物(300406)6月30日股东户数1.97万户，较上期减少7.11%
证券之星 · 08-22
九强生物(300406)6月30日股东户数1.97万户，较上期减少7.11%
图解九强生物中报：第二季度单季净利润同比增长13.83%
证券之星 · 08-22
图解九强生物中报：第二季度单季净利润同比增长13.83%
九强生物（300406）披露2026年半年度报告，8月21日股价下跌3.62%
证券之星 · 08-21
九强生物（300406）披露2026年半年度报告，8月21日股价下跌3.62%
股市必读：九强生物新发布《关于副董事长、总经理离任的公告》
证券之星 · 08-03
股市必读：九强生物新发布《关于副董事长、总经理离任的公告》
股市必读：新发布《北京九强生物技术股份有限公司公开发行可转换公司债券第四次临时受托管理事务报告（2026年度）》
证券之星 · 07-31
股市必读：新发布《北京九强生物技术股份有限公司公开发行可转换公司债券第四次临时受托管理事务报告（2026年度）》
九强生物（300406）披露限制性股票回购注销完成公告，7月30日股价上涨0.53%
证券之星 · 07-30
九强生物（300406）披露限制性股票回购注销完成公告，7月30日股价上涨0.53%
九强生物（300406）披露部分限制性股票回购注销完成公告，7月24日股价下跌2.38%
证券之星 · 07-24
九强生物（300406）披露部分限制性股票回购注销完成公告，7月24日股价下跌2.38%
九强生物（300406）披露取得两项医疗器械注册证书公告，7月9日股价下跌1.41%
证券之星 · 07-09
九强生物（300406）披露取得两项医疗器械注册证书公告，7月9日股价下跌1.41%
九强生物最新公告：取得两项医疗器械注册证书
证券之星 · 07-09
九强生物最新公告：取得两项医疗器械注册证书
九强生物（300406）披露2025年度可转换公司债券受托管理事务报告，6月29日股价上涨4.07%
证券之星 · 06-29
九强生物（300406）披露2025年度可转换公司债券受托管理事务报告，6月29日股价上涨4.07%
九强生物（300406）披露取得医疗器械注册证书公告，6月23日股价上涨2.39%
证券之星 · 06-23
九强生物（300406）披露取得医疗器械注册证书公告，6月23日股价上涨2.39%
九强生物(300406.SZ)取得一项医疗器械注册证书
智通财经 · 06-23
九强生物(300406.SZ)取得一项医疗器械注册证书
每周股票复盘：九强生物（300406）股东终止转让5%股份
证券之星 · 06-21
每周股票复盘：九强生物（300406）股东终止转让5%股份
九强生物（300406）披露股东终止协议转让部分股份公告，6月18日股价上涨0.35%
证券之星 · 06-18
九强生物（300406）披露股东终止协议转让部分股份公告，6月18日股价上涨0.35%
九强生物(300406.SZ)：两款产品取得医疗器械注册证书
智通财经 · 06-08
九强生物(300406.SZ)：两款产品取得医疗器械注册证书
加载更多
公司概况
公司名称：
北京九强生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2014-10-30
主营业务：
北京九强生物技术股份有限公司的主营业务是体外诊断试剂及体外诊断仪器的生产及销售。公司的主要产品是病理诊断系统、生化诊断系统、血凝诊断系统、发光诊断系统、血型诊断系统、POCT诊断系统和液体活检系统。
发行价格：
14.32
{"stockData":{"symbol":"300406","market":"SZ","secType":"STK","nameCN":"九强生物","latestPrice":11.78,"timestamp":1788505422000,"preClose":11.73,"halted":0,"volume":4729428,"delay":0,"changeRate":0.0043,"floatShares":424000000,"shares":586000000,"eps":0.3838,"marketStatus":"已收盘","change":0.05,"latestTime":"09-04 15:00:00","open":11.8,"high":11.9,"low":11.68,"amount":55822500,"amplitude":0.0188,"askPrice":11.78,"askSize":76,"bidPrice":11.77,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.3838,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":5,"adr":0,"adjPreClose":11.73,"symbolType":"stock","openAndCloseTimeList":[[1788485400000,1788492600000],[1788498000000,1788505200000]],"highLimit":12.9,"lowLimit":10.56,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":586140466,"isCdr":false,"pbRate":2,"roa":"--","peRate":30.693069,"roe":"5.59%","epsLYR":0.32,"committee":-0.051525,"marketValue":6905000000,"turnoverRate":0.0111,"status":0,"floatMarketCap":4998000000},"requestUrl":"/m/hq/s/300406","defaultTab":"news","newsList":[{"id":"2664890538","title":"九强生物最新公告：取得叶酸测定试剂盒医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2664890538","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664890538?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:16","pubTimestamp":1788340607,"startTime":"0","endTime":"0","summary":"九强生物(300406.SZ)公告称，公司近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品为叶酸测定试剂盒(磁微粒化学发光免疫分析法)，注册类别为Ⅱ类，有效期至2031年8月26日，用于体外定量测定人血清或血浆中叶酸含量。该注册证的取得丰富了公司在体外诊断化学发光细分领域产品线，有利于提升核心竞争力，但实际销售情况取决于市场推广效果，对业绩影响尚无法预测。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200030396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0046","BK0012","BK1100","159883","09996","300406","BK1574","BK0028","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664663948","title":"股市必读：九强生物新发布《第五届董事会第二十七次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664663948","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664663948?lang=zh_cn&edition=full","pubTime":"2026-09-02 03:23","pubTimestamp":1788290613,"startTime":"0","endTime":"0","summary":"为保障董事会正常运作，经股东中国医药投资有限公司提名，董事会提名委员会审核通过，董事会同意提名英军先生为第五届董事会非独立董事候选人，任期自股东大会审议通过之日起至本届董事会任期届满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200004121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406","BK0012","BK0028","BK0239","BK0046","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664595850","title":"九强生物（300406）披露召开2026年第二次临时股东会的通知，9月1日股价上涨1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664595850","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664595850?lang=zh_cn&edition=full","pubTime":"2026-09-01 23:12","pubTimestamp":1788275538,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，九强生物报收于11.85元，较前一交易日上涨1.11%，最新总市值为69.46亿元。该股当日开盘11.66元，最高11.86元，最低11.64元，成交额达6178.5万元，换手率为1.24%。近日，北京九强生物技术股份有限公司披露《关于召开2026年第二次临时股东会的通知》。公告显示，公司将于2026年9月17日召开2026年第二次临时股东会，会议采取现场表决与网络投票相结合的方式，股权登记日为2026年9月10日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0046","BK0239","BK0028","BK0077","300406"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662434757","title":"股市必读：九强生物（300406）8月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2662434757","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662434757?lang=zh_cn&edition=full","pubTime":"2026-08-26 05:53","pubTimestamp":1787694793,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，九强生物报收于11.65元，上涨1.22%，换手率1.08%，成交量4.59万手，成交额5291.27万元。董秘最新回复投资者： 公司2025年12月9日发布股东拟协议转让部分股份的公告。一直到2026年6月18日才公告股东终止转让股份。协议中表明2025 年 12 月 31 日止，未能在前述期间内办理完成标的股份过户登记，自 2026 年 1 月 1 日起，一方有权书面通知另一方解除本协议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600008691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0046","300406","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661721265","title":"九强生物（300406）2026年中报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2661721265","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661721265?lang=zh_cn&edition=full","pubTime":"2026-08-23 06:14","pubTimestamp":1787436881,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期九强生物发布2026年中报。截至本报告期末，公司营业总收入6.79亿元，同比上升1.55%，归母净利润2.1亿元，同比上升20.02%。按单季度数据看，第二季度营业总收入3.44亿元，同比下降1.34%，第二季度归母净利润1.05亿元，同比上升13.83%。本报告期九强生物盈利能力上升，毛利率同比增幅1.6%，净利率同比增幅17.88%。投资活动产生的现金流量净额变动幅度为176.42%,原因:大额存单收回。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300001994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661227216","title":"九强生物(300406)6月30日股东户数1.97万户，较上期减少7.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661227216","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661227216?lang=zh_cn&edition=full","pubTime":"2026-08-22 17:09","pubTimestamp":1787389770,"startTime":"0","endTime":"0","summary":"证券之星消息，近日九强生物披露，截至2026年6月30日公司股东户数为1.97万户，较3月31日减少1510.0户，减幅为7.11%。户均持股数量由上期的2.76万股增加至2.97万股，户均持股市值为32.48万元。在医疗器械行业个股中，九强生物股东户数低于行业平均水平，截至6月30日，医疗器械行业平均股东户数为2.15万户。根据统计，九强生物2026年3月31日至2026年6月30日，主力资金净流出8297.14万元，游资资金净流入290.34万元，散户资金净流入8006.8万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200015069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300406","BK0012","BK0046","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661294192","title":"图解九强生物中报：第二季度单季净利润同比增长13.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661294192","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661294192?lang=zh_cn&edition=full","pubTime":"2026-08-22 01:23","pubTimestamp":1787332984,"startTime":"0","endTime":"0","summary":"证券之星消息，九强生物2026年中报显示，上半年度公司主营收入6.79亿元，同比上升1.55%；归母净利润2.1亿元，同比上升20.02%；扣非净利润2.06亿元，同比上升18.86%；其中2026年第二季度，公司单季度主营收入3.44亿元，同比下降1.34%；单季度归母净利润1.05亿元，同比上升13.83%；单季度扣非净利润1.03亿元，同比上升13.22%；负债率26.48%，投资收益733.62万元，财务费用2123.66万元，毛利率80.86%。财报数据概要请见下图:本文数据来源于九强生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200001752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661296200","title":"九强生物（300406）披露2026年半年度报告，8月21日股价下跌3.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661296200","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661296200?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:36","pubTimestamp":1787322969,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，九强生物报收于11.7元，较前一交易日下跌3.62%，最新总市值为68.58亿元。该股当日开盘11.92元，最高11.97元，最低11.58元，成交额达8456.42万元，换手率为1.7%。近日，九强生物披露《2026年半年度报告》。经营活动产生的现金流量净额为246,795,816.50元，同比增长1.11%。截至报告期末，公司存续债券“九强转债”余额为112,102.21万元，资产负债率为26.48%，EBITDA利息保障倍数为12.18。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100046228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","300406","BK0046","BK0239","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656348249","title":"股市必读：九强生物新发布《关于副董事长、总经理离任的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656348249","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656348249?lang=zh_cn&edition=full","pubTime":"2026-08-03 01:48","pubTimestamp":1785692894,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，九强生物报收于11.64元，上涨2.28%，换手率1.66%，成交量7.05万手，成交额8172.76万元。当日关注点交易信息汇总：7月31日主力资金净流出694.17万元，占总成交额8.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","300406","BK0046","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655800347","title":"股市必读：新发布《北京九强生物技术股份有限公司公开发行可转换公司债券第四次临时受托管理事务报告（2026年度）》","url":"https://stock-news.laohu8.com/highlight/detail?id=2655800347","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655800347?lang=zh_cn&edition=full","pubTime":"2026-07-31 02:17","pubTimestamp":1785435431,"startTime":"0","endTime":"0","summary":"公司公告汇总北京九强生物技术股份有限公司公开发行可转换公司债券第四次临时受托管理事务报告北京九强生物技术股份有限公司因第五期限制性股票激励计划预留授予第二个解除限售期公司层面业绩考核未达标，对7名激励对象合计168,162股限制性股票进行回购注销，占注销前总股本的0.03%。回购总价为1,363,793.82元，已于2026年7月23日完成注销，公司总股本由586,308,628股减少至586,140,466股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0028","300406","BK0046","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655066858","title":"九强生物（300406）披露限制性股票回购注销完成公告，7月30日股价上涨0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655066858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655066858?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:34","pubTimestamp":1785422055,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，九强生物报收于11.38元，较前一交易日上涨0.53%，最新总市值为66.7亿元。近日，北京九强生物技术股份有限公司披露公告，因第五期限制性股票激励计划预留授予第二个解除限售期公司层面业绩考核未达标，对7名激励对象合计168,162股限制性股票进行回购注销，占注销前总股本的0.03%。回购总价为1,363,793.82元，已于2026年7月23日完成注销，公司总股本由586,308,628股减少至586,140,466股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000039958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406","BK0012","BK0028","BK0046","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653033900","title":"九强生物（300406）披露部分限制性股票回购注销完成公告，7月24日股价下跌2.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653033900","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653033900?lang=zh_cn&edition=full","pubTime":"2026-07-24 22:45","pubTimestamp":1784904316,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，九强生物报收于11.08元，较前一交易日下跌2.38%，最新总市值为64.96亿元。该股当日开盘11.2元，最高11.35元，最低11.07元，成交额达3239.69万元，换手率为0.68%。公告显示，因第五期限制性股票激励计划预留授予第二个解除限售期公司层面业绩考核不达标，公司回购注销7名激励对象持有的限制性股票共计168,162股，占注销前总股本的0.03%。本次回购注销已于2026年7月23日完成，公司总股本由586,308,628股减少至586,140,466股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400042533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300406","BK0012","BK0028","BK0077","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650920098","title":"九强生物（300406）披露取得两项医疗器械注册证书公告，7月9日股价下跌1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650920098","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650920098?lang=zh_cn&edition=full","pubTime":"2026-07-09 22:31","pubTimestamp":1783607470,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘，九强生物报收于11.17元，较前一交易日下跌1.41%，最新总市值为65.49亿元。该股当日开盘11.33元，最高11.44元，最低11.0元，成交额达4681.6万元，换手率为0.99%。九强生物于近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品为抗凝血酶Ⅲ测定试剂盒和骨钙素测定试剂盒，注册类别均为Ⅱ类，有效期均至2031年7月5日。实际销售情况取决于市场推广效果，目前尚无法预测其对未来业绩的具体影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900042622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0028","BK0077","159883","09996","BK1583","BK1100","BK0046","BK0012","BK0239","300406"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650947000","title":"九强生物最新公告：取得两项医疗器械注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2650947000","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650947000?lang=zh_cn&edition=full","pubTime":"2026-07-09 17:05","pubTimestamp":1783587930,"startTime":"0","endTime":"0","summary":"九强生物(300406.SZ)公告称，公司近日收到北京市药品监督管理局颁发的《医疗器械注册证》，包括抗凝血酶Ⅲ测定试剂盒(发色底物法)和骨钙素测定试剂盒(磁微粒化学发光免疫分析法)两项产品。上述注册证的取得丰富了公司在体外诊断凝血和化学发光细分领域的产品线，有利于提升核心竞争力和市场拓展能力，但实际销售情况取决于未来市场推广效果，投资者需注意投资风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900029536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1100","BK0028","BK0012","159883","BK0046","09996","BK0077","BK1574","BK0239","300406","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647784613","title":"九强生物（300406）披露2025年度可转换公司债券受托管理事务报告，6月29日股价上涨4.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647784613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647784613?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:06","pubTimestamp":1782727615,"startTime":"0","endTime":"0","summary":"截至2026年6月29日收盘，九强生物报收于11.26元，较前一交易日上涨4.07%，最新总市值为66.02亿元。近日，北京九强生物技术股份有限公司发布《中国国际金融股份有限公司关于北京九强生物技术股份有限公司可转换公司债券受托管理事务报告》。2025年公司营业收入13.56亿元，同比下降18.29%；归母净利润1.90亿元，同比下降64.35%。报告期内未发生债券持有人会议事项，偿债保障措施有效执行，未触发回售条款，董事会两次决定不向下修正转股价格。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900029064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0028","300406","BK0046","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645467832","title":"九强生物（300406）披露取得医疗器械注册证书公告，6月23日股价上涨2.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645467832","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645467832?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:24","pubTimestamp":1782224667,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，九强生物报收于11.55元，较前一交易日上涨2.39%，最新总市值为67.72亿元。九强生物于近日披露《关于取得医疗器械注册证书的公告》。公告显示，公司近日收到国家药品监督管理局颁发的《医疗器械注册证》，产品为人ABO血型反定型用红细胞试剂盒，注册证编号为国械注准20263401280，注册类别为Ⅲ类，有效期至2031年6月21日。该产品用于临床检验中的人ABO血型反定型检测，不用于血源筛查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","09996","159883","BK0239","BK1100","BK0046","BK0012","BK1574","BK0028","BK1583","300406"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645688645","title":"九强生物(300406.SZ)取得一项医疗器械注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2645688645","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645688645?lang=zh_cn&edition=full","pubTime":"2026-06-23 15:46","pubTimestamp":1782200812,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九强生物(300406.SZ)发布公告，公司于近日收到国家药品监督管理局颁发的《医疗器械注册证》，产品名称：人ABO血型反定型用红细胞试剂盒，该产品用于人ABO血型反定型检测，仅用于临床检验，不用于血源筛查。上述产品医疗器械注册证的取得，丰富了公司在体外诊断血型领域产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公司未来的经营将产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0077","300406","BK1574","BK0028","09996","BK1100","BK0046","BK1583","BK0239","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645009988","title":"每周股票复盘：九强生物（300406）股东终止转让5%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645009988","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645009988?lang=zh_cn&edition=full","pubTime":"2026-06-21 03:44","pubTimestamp":1781984653,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，九强生物报收于11.34元，较上周的11.54元下跌1.73%。本周关注点公司公告汇总：股东终止向中国医药投资转让5.0000003%股份公司公告汇总关于股东终止协议转让部分股份的公告北京九强生物技术股份有限公司股东邹左军、刘希、孙小林与中国医药投资有限公司于2025年12月8日签署《股份转让协议》，拟协议转让公司29,315,433股股份，占公司总股本的5.0000003%。截至2025年12月31日，标的股份未完成过户登记。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100001289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0046","300406","BK0012","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644825670","title":"九强生物（300406）披露股东终止协议转让部分股份公告，6月18日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644825670","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644825670?lang=zh_cn&edition=full","pubTime":"2026-06-18 23:00","pubTimestamp":1781794850,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，九强生物报收于11.34元，较前一交易日上涨0.35%，最新总市值为66.49亿元。公司于近日披露《关于股东终止协议转让部分股份的公告》。公告显示，北京九强生物技术股份有限公司股东邹左军、刘希、孙小林与中国医药投资有限公司于2025年12月8日签署《股份转让协议》，拟协议转让公司29,315,433股股份，占公司总股本的5.0000003%。截至2025年12月31日，标的股份未完成过户登记。根据协议约定，自2026年1月1日起，一方有权解除协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800043136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0046","BK0028","BK0012","300406"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641044461","title":"九强生物(300406.SZ)：两款产品取得医疗器械注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2641044461","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641044461?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:52","pubTimestamp":1780905120,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 九强生物(300406.SZ)发布公告，公司于近日收到北京市药品监督管理局颁发的《医疗器械注册证》，涉及产品：“可溶性生长刺激表达基因2蛋白测定试剂盒(胶乳免疫比浊法)”、“全自动凝血分析仪(型号：MDC3600、 MDC2600)”。上述产品医疗器械注册证的取得，丰富了公司在体外诊断生化和凝血分析仪器细分领域产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公司未来的经营将产生积极影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","159883","BK0046","BK1583","BK0012","300406","BK0028","BK1574","BK0077","BK0239","09996"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788566146418,"stockEarnings":[{"period":"1week","weight":0.0172},{"period":"1month","weight":0.0233},{"period":"3month","weight":-0.0015},{"period":"6month","weight":0.0043},{"period":"1year","weight":-0.0749},{"period":"ytd","weight":-0.0334}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":0.0133},{"period":"3month","weight":-0.0242},{"period":"6month","weight":-0.0471},{"period":"1year","weight":0.0436},{"period":"ytd","weight":-0.0098}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京九强生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19732人(较上一季度减少7.11%)","perCapita":"21502股","listingDate":"2014-10-30","address":"北京市海淀区花园东路15号旷怡大厦5层","registeredCapital":"58614万元","survey":" 北京九强生物技术股份有限公司的主营业务是体外诊断试剂及体外诊断仪器的生产及销售。公司的主要产品是病理诊断系统、生化诊断系统、血凝诊断系统、发光诊断系统、血型诊断系统、POCT诊断系统和液体活检系统。","listedPrice":14.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九强生物(300406)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九强生物(300406)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九强生物,300406,九强生物股票,九强生物股票老虎,九强生物股票老虎国际,九强生物行情,九强生物股票行情,九强生物股价,九强生物股市,九强生物股票价格,九强生物股票交易,九强生物股票购买,九强生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九强生物(300406)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九强生物(300406)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}